What does the Philippine clinical practice guideline recommend for diagnosing and treating urinary tract infections in adults (including uncomplicated cystitis), pregnant women, and pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

UTI Clinical Practice Guidelines – Philippines

First-Line Antibiotic Therapy for Uncomplicated Cystitis in Adults

For otherwise healthy, non-pregnant Filipino adults with uncomplicated cystitis, prescribe nitrofurantoin 100 mg orally twice daily for 5 days as the preferred first-line agent. 1, 2

Primary Treatment Options

  • Nitrofurantoin 100 mg PO BID × 5 days achieves approximately 93% clinical cure and 88% microbiological eradication, with worldwide resistance rates below 1% and minimal disruption of intestinal flora. 1, 2

  • Fosfomycin trometamol 3 g as a single oral dose provides 91% clinical cure with therapeutic urinary concentrations maintained for 24–48 hours; this single-dose regimen maximizes adherence. 1, 2

  • Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg PO BID × 3 days should be used only when local E. coli resistance is <20% and the patient has not received TMP-SMX in the preceding 3 months; verify local antibiogram data before prescribing. 1, 2

Contraindications to First-Line Agents

  • Avoid nitrofurantoin when estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m² or for suspected pyelonephritis, because adequate urinary concentrations cannot be achieved. 1

  • Do not use fosfomycin for suspected pyelonephritis or upper urinary tract infections due to insufficient tissue penetration. 1

  • Do not prescribe TMP-SMX empirically unless local E. coli resistance is confirmed <20%; treatment failure rates rise sharply above this threshold. 1


Reserve (Second-Line) Agents – Use Only After Culture-Proven Resistance

  • Fluoroquinolones (ciprofloxacin 250–500 mg PO BID or levofloxacin 250–750 mg PO daily × 3 days) should be reserved exclusively for culture-proven resistant pathogens or documented failure of first-line therapy, because serious adverse effects (tendon rupture, peripheral neuropathy, CNS toxicity) outweigh benefits in uncomplicated UTI. 1

  • Beta-lactams (amoxicillin-clavulanate, cefdinir, cefpodoxime × 3–7 days) achieve only 89% clinical cure and 82% microbiological eradication—significantly inferior to first-line agents—and should be used only when all first-line options are contraindicated. 1, 2

  • Amoxicillin or ampicillin alone should never be used because worldwide E. coli resistance exceeds 55–67%. 1


Diagnostic Recommendations

When Urine Culture Is NOT Required

  • Routine urine culture is unnecessary for otherwise healthy women presenting with typical lower urinary tract symptoms (dysuria, frequency, urgency) in the absence of vaginal discharge. 1, 2

When Urine Culture IS Mandatory

Obtain urine culture and susceptibility testing when any of the following occur: 1, 2

  • Persistent symptoms after completing the prescribed regimen
  • Recurrence of symptoms within 2–4 weeks
  • Fever >38°C, flank pain, or costovertebral angle tenderness (suggesting pyelonephritis)
  • Atypical presentation or presence of vaginal discharge
  • Pregnancy with urinary symptoms
  • History of recurrent infections or prior resistant organisms

Management of Treatment Failure

  • If symptoms persist after 2–3 days or recur within 2 weeks, obtain urine culture and susceptibility testing immediately, then switch to a different antibiotic class for a 7-day course (not the original short regimen). 1, 2

  • Assume the original pathogen is resistant to the initially used agent when retreating. 1

  • Reserve fluoroquinolones only for culture-proven resistance to all first-line agents. 1


Acute Pyelonephritis (Upper Urinary Tract Infection)

For suspected pyelonephritis (fever >38°C, flank pain, CVA tenderness), do not use nitrofurantoin or fosfomycin; instead prescribe:

  • Ciprofloxacin 500–750 mg PO BID × 7 days or levofloxacin 750 mg PO daily × 5–7 days if local fluoroquinolone resistance is <10%. 1, 2

  • Ceftriaxone 1–2 g IV once daily for patients requiring parenteral therapy or when fluoroquinolone resistance exceeds 10%. 1, 2

  • If fever persists beyond 72 hours, perform renal ultrasound or CT imaging to exclude obstruction or abscess. 1


Pregnancy-Specific Recommendations

First-Line Options for Pregnant Women

  • Fosfomycin 3 g single oral dose is safe throughout all trimesters and preferred for both asymptomatic bacteriuria and symptomatic cystitis. 1

  • Nitrofurantoin 100 mg PO BID × 5–7 days is safe in pregnancy but should be avoided after 36 weeks gestation due to theoretical risk of neonatal hemolytic anemia. 1

  • Amoxicillin 500 mg PO TID × 3–7 days is safe in all trimesters when the organism is susceptible. 1

Agents to Avoid in Pregnancy

  • Avoid TMP-SMX in the first trimester (neural tube defect risk) and third trimester (neonatal hyperbilirubinemia/kernicterus risk); may consider in second trimester only if local resistance is <20% and other agents are unsuitable. 1

  • Mandatory urine culture before initiating therapy in any pregnant woman with urinary symptoms. 1

  • Post-treatment urine culture 7 days after completing therapy to confirm microbiological cure. 1


Pediatric UTI Management

Diagnostic Criteria

  • Pyuria (≥10 WBC/HPF or positive leukocyte esterase) plus acute urinary symptoms (dysuria, frequency, urgency, fever >38.3°C, or gross hematuria) must both be present before starting antimicrobial therapy. 3

  • The absence of pyuria can help rule out infection in most pediatric populations, but the positive predictive value of pyuria alone is exceedingly low. 3

Treatment Principles

  • Evidence-based diagnosis should be primarily based on clinical symptoms, integrated with urinalysis findings; do not rely solely on urinalysis alone. 3

  • Urine cultures are reasonable for complicated cases, recurrent UTIs, or suspected pyelonephritis to guide targeted therapy; routine cultures are not necessary for simple uncomplicated cystitis in healthy children. 3


Critical Pitfalls to Avoid

  • Do not treat asymptomatic bacteriuria in non-pregnant, non-catheterized patients; this promotes resistance without clinical benefit and paradoxically increases recurrent UTI episodes. 1, 2

  • Do not use empiric fluoroquinolones as first-line therapy for uncomplicated cystitis; reserve them for complicated infections or culture-proven resistance. 1, 2

  • Do not prescribe nitrofurantoin for suspected pyelonephritis or when eGFR <30 mL/min/1.73 m². 1

  • Do not use oral fosfomycin for suspected upper urinary tract infection or pyelonephritis. 1

  • Verify local TMP-SMX resistance patterns before empirical use; if data are unavailable, default to nitrofurantoin or fosfomycin. 1


Recurrent UTI Prevention Strategies

For Postmenopausal Women

  • Vaginal estrogen therapy (with or without lactobacillus-containing probiotics) reduces future UTI risk. 2

For Premenopausal Women

  • Post-coital prophylaxis: Low-dose antibiotic within 2 hours of sexual activity for 6–12 months for women with post-coital infections. 2

  • Daily prophylaxis: Nitrofurantoin for 6–12 months for patients with ≥3 UTIs per year (or ≥2 in 6 months) unrelated to sexual activity. 2

Non-Antibiotic Alternatives

  • Methenamine hippurate (alone or with lactobacillus probiotics) is an acceptable non-antibiotic prophylactic option. 2

  • Cranberry products in tolerable formulations may be used as adjunctive preventive measures. 2

  • Maintain adequate hydration, void shortly after sexual activity, and avoid spermicide-containing contraceptives. 2

References

Guideline

Fosfomycin Treatment for Uncomplicated Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment for Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the recommended treatment for urinary‑tract‑infection‑related pain in an otherwise healthy non‑pregnant adult woman with uncomplicated cystitis?
How do complicated and uncomplicated cystitis differ, and why do they require different antimicrobial regimens and treatment durations?
What is the optimal first‑line therapy for an uncomplicated cystitis in a healthy 17‑year‑old female who is not pregnant and has no drug allergies or renal impairment?
What is the recommended treatment for acute cystitis?
In an 84-year-old female with acute cystitis requiring IV antibiotics and urine‑related groin excoriation with pruritus, what skin‑protective regimen should be used?
What is the appropriate management for balanitis?
Is there any herb or dietary supplement recommended as a first‑line treatment for the physical symptoms of anxiety in an adult who is already using diaphragmatic breathing, progressive muscle relaxation, mindfulness‑based stress reduction, regular aerobic exercise, and brief cognitive‑behavioral therapy?
Can clindamycin be used to treat a cutaneous abscess, and what are the appropriate indications and dosing?
In a patient with a possible but unidentified cardiac channelopathy, which second‑generation H1 antihistamine—cetirizine (Zyrtec) or fexofenadine (Allegra)—carries a higher risk of affecting cardiac rhythm?
How long can Elocom 0.1% scalp lotion (mometasone furoate) be used?
What is gamma‑glutamyl transferase (GGT) and what does an elevated level signify in a patient with one‑week epigastric/right upper quadrant pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.